摘要
AIM： To observe the therapeutic effects of liposomeencapsulated adriamycin （LADM） on hepatoma in comparison with adriamycin solution （FADM） and adriarnycin plus blank liposome （ADM ＋ BL） administered into the hepatic artery of rats. METHODS： LADM was prepared by pH gradient-driven method. Normal saline, FADM （2 mg/kg）, ADM＋BL （2 mg/kg）, and LADM （2 mg/kg） were injected via the hepatic artery in rats bearing liver W256 carcinosarcoma, which were divided into four groups randomly. The therapeutic effects were evaluated in terms of survival time, tumor enlargement ratio, and tumor necrosis degree. The difference was determined with ANOVA and Dunnett test and log rank test. RESULTS： Compared to FADM or ADM ＋ BL, LADM produced a more significant tumor inhibition （tumor volume ratio： 1.243±0.523 vs 1.883±0.708, 1.847±0.661, P 〈 0.01）, and more extensive tumor necrosis. The increased life span was prolonged significantly in rats receiving LADM compared with FADM or ADM＋BL （231.48 vs 74.66, 94.70） （P 〈 0.05）. CONCLUSION： The anticancer efficacies of adriamycin on hepatoma can be strongly improved by liposomal encapsulation through hepatic arterial administration.
瞄准：加空白与 adriamycin 答案(FADM ) 和 adriamycin 比较在肝细胞瘤上观察包含 liposome 的 adriamycin (LADM ) 的治疗学的效果脂肪一些(ADM + BL ) 管理了进老鼠的肝的动脉。方法：LADM 被 pH 准备坡度驱动的方法。生理盐水， FADM (2 mg/kg ) ， ADM+BL (2 mg/kg ) ，和 LADM (2 mg/kg ) 在忍受肝 W256 癌肉瘤的老鼠经由肝的动脉被注射，它随机被划分成四个组。治疗学的效果以生存时间，肿瘤增大比率，和肿瘤坏死度被评估。差别与 ANOVA 和 Dunnett 测试和木头等级测试被决定。结果：比作 FADM 或 ADM + BL， LADM 生产了更重要的肿瘤抑制(肿瘤体积比率：1.243 +/- 0.523 对 1.883 +/- 0.708， 1.847 +/- 0.661， P < 0.01 ) ，并且更广泛的肿瘤坏死。增加的寿命在与 FADM 或 ADM+BL 相比收到 LADM 的老鼠显著地被延长(231.48 对 74.66， 94.70 )(P < 0.05 ) 。结论：肝细胞瘤上的 adriamycin 的反癌症功效能被 liposomal 封装强烈通过肝的动脉的管理改进。
